Rhythm Diagnostic Systems SAS (RDS) raised €14 million (US$16.6 million) in a series A funding round for Multisense, its wearable device that continuously monitors key physiological parameters of ...

Genmab A/S is paying $8 billion to acquire Merus NV, gaining rights to the latter’s phase III-stage petosemtamab, a ...

Antibodies that bind to sugars on the surface of cancer cells, rather than to proteins, have not yielded satisfactory results so far due to their low binding affinity. However, scientists at the ...

Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...

The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as ...

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab ...

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but ...

After a phase III stumble, Acadia Pharmaceuticals Inc. will drop development of ACP-101, intranasal carbetocin, to treat ...

Nailing down what Oppenheimer analyst Jay Olson characterized as “a trifecta,” Immuneering Corp. unveiled positive updated survival and safety data from the ongoing phase IIa trial testing oral, ...

The struggle to avoid a partial U.S. government shutdown at midnight Sept. 30 is getting a lot of attention, as the stakes increase every day of the political standoff. Meanwhile, Sept. 30 also could ...